Media coverage about BioDelivery Sciences International (NASDAQ:BDSI) has been trending somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioDelivery Sciences International earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 47.6438069020487 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern’s rankings:
Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded up $0.02 during trading hours on Tuesday, hitting $2.67. The stock had a trading volume of 747,937 shares, compared to its average volume of 538,640. BioDelivery Sciences International has a one year low of $1.55 and a one year high of $3.60. The company has a current ratio of 1.28, a quick ratio of 1.07 and a debt-to-equity ratio of 1.89.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. The company had revenue of $11.25 million for the quarter, compared to analyst estimates of $9.40 million. During the same quarter last year, the firm earned ($0.30) EPS. BioDelivery Sciences International’s revenue for the quarter was up 215.1% compared to the same quarter last year. research analysts expect that BioDelivery Sciences International will post 0.16 EPS for the current year.
A number of research firms have issued reports on BDSI. ValuEngine lowered BioDelivery Sciences International from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Piper Jaffray Companies set a $4.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Wednesday, August 9th. Roth Capital set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Thursday, October 12th. HC Wainwright set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a report on Thursday, August 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.50 target price on shares of BioDelivery Sciences International in a report on Monday, August 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $4.29.
In related news, CEO Mark A. Sirgo sold 24,516 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of $2.75, for a total transaction of $67,419.00. Following the completion of the transaction, the chief executive officer now owns 1,509,262 shares in the company, valued at approximately $4,150,470.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Mark A. Sirgo sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $2.95, for a total value of $147,500.00. Following the transaction, the chief executive officer now owns 1,509,262 shares of the company’s stock, valued at approximately $4,452,322.90. The disclosure for this sale can be found here. Insiders have sold a total of 402,127 shares of company stock worth $1,142,798 in the last three months. 7.73% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “BioDelivery Sciences International (BDSI) Given Media Sentiment Score of 0.12” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/12/05/biodelivery-sciences-international-bdsi-earning-somewhat-favorable-media-coverage-study-shows.html.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.